Incyte (INCY) PT Raised to $113 at RBC

October 12, 2016 11:48 AM EDT
Get Alerts INCY Hot Sheet
Price: $88.38 +0.48%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 11
Trade INCY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst Simos Simeonidis reiterated an Outperform rating and boosted his price target on Incyte (NASDAQ: INCY) to $113.00 (from $106.00) following the epacadostat update at ESMO

Simeonidis commented, "Despite what we acknowledge is a small sample size, and the fact that we’ve only seen very strong evidence of its activity and safety in one tumor type (melanoma), we remain impressed by the data and are thus raising the probability of success for the drug in this indication."

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $92.11 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

RBC Capital

Add Your Comment